The Effect of Intratracheal Furosemide, Salbutamol, or a Mixture of Both with Surfactant on Clinical Course of Neonatal Respiratory Distress Syndrome

Evaluation of the Effect of Intratracheal Furosemide, Salbutamol, or a Mixture of Both with Surfactant on Clinical Course of Premature Infants with Respiratory Distress Syndrome

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2014072714215N1

Enrollment

Registered

2014-08-13

Start date

2014-03-21

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Respiratory Distress Syndrome. certain conditions originating in the perinatal period

Interventions

Intervention 1: Furosemide 1mg.kg.body weight accompanied Surfactant would be infused in trachea. if needing to repeated dose of Surfactant, Furosemide also would be repeated. Intervention 2: Salbutam

Treatment - Drugs

Furosemide 1mg.kg.body weight accompanied Surfactant would be infused in trachea. if needing to repeated dose of Surfactant, Furosemide also would be repeated.

Salbutamol 0.2mg.kg.body weight accompanied Surfactant would be infused in trachea. if needing to repeated dose of surfactant, Salbutamol also would be repeated

Furosemide 1mg.kg.body weight and Salbutamol 0.2 mg.kg.body weight accompanied Surfactant would be infused in trachea. if needing to repeated dose of surfactant, Furosemide and Salbutamol also would b

Normal Saline 0.5ml.kg.body weight as placebo accompanied Surfactant would be infused in trachea. if needing to repeated dose of Surfactant, Normal Saline also would be repeated

Eligibility

Sex/Gender

All

Age

1 Days to 1 Months

Inclusion criteria

Inclusion criteria: Inclusion criteria: newborns with gestational less than 34 weeks; respiratory distress syndrome and Exclusion criteria: birth weight less than 1000gr; birth trauma; congenital anomalies; birth asphyxia; transported patients

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Clinical course. Timepoint: Discharge from hospital. Method of measurement: Hours and days that patients needing to respiratory therapy.	—

Secondary

Measure	Time frame
Death. Timepoint: Cardiorespiratory arrest. Method of measurement: Absent of heart beat and respiratory movement.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDehdashtian Masoud

Medical Faculty

dehdashtian@ajums.ac.ir+98 61 1221 6501

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Mar 2, 2026